Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02502162 · ClinicalTrials.gov registry record · NA
Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome
A NA study of Complex Regional Pain Syndrome, sponsored by Stanford University.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT02502162 is a NA study of Complex Regional Pain Syndrome that is actively recruiting participants, run by Stanford University. The registered enrollment target is 120 participants, below the 231-participant average among 3 other Complex Regional Pain Syndrome trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02502162, a NA study of Complex Regional Pain Syndrome, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to attend either in-person or virtual study visits and complete questionnaires.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LDN
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2015-06 |
| Est. Completion | 2027-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02502162
The ClinicalTrials.gov registry entry for NCT02502162 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 231-participant average among 3 other Complex Regional Pain Syndrome trials with a reported enrollment target (48% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Complex Regional Pain Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02502162 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02502162 about?
NCT02502162 is a clinical study titled "Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome". The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to attend eit...
What is the current status of trial NCT02502162?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2015-06. Estimated completion is 2027-07.
What conditions does trial NCT02502162 study?
This clinical trial studies the following conditions: Complex Regional Pain Syndrome.
What interventions are being tested in trial NCT02502162?
The interventions under investigation include: Placebo (DRUG), LDN (DRUG).
Who is sponsoring clinical trial NCT02502162?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02502162 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Complex Regional Pain Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome
RECRUITING · Phase 1
-
Safety of Intravenous Neridronic Acid in CRPS
COMPLETED · Phase 3
-
A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.